abrocitinib (Cibinqo)
Jump to navigation
Jump to search
Indications
Dosage
Adverse effects
* dose-dependent (% for 200 mg dose)
Mechanism of action
- Janus kinase 1 (JAK1) inhibitor
- reduces interleukin-4 & interleukin-13 signaling
More general terms
References
- ↑ Bieber T, Simpson EL, Silverberg JT et al Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med 2021; 384:1101-1112. March 25 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33761207 https://www.nejm.org/doi/full/10.1056/NEJMoa2019380
- ↑ Highlights of Prescribing Information CIBINQO <TM> (abrocitinib) tablets, for oral use https://labeling.pfizer.com/ShowLabeling.aspx?id=16652